Gaboxadol
- Generic Name
- Gaboxadol
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8N2O2
- CAS Number
- 64603-91-4
- Unique Ingredient Identifier
- K1M5RVL18S
- Background
Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing effects of benzodiazepines. Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.
- Indication
Investigated for use/treatment in sleep disorders and insomnia.
Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Craig Erickson
- Target Recruit Count
- 10
- Registration Number
- NCT06334419
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40
- Conditions
- Fragile X Syndrome
- Interventions
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Healx Limited
- Registration Number
- NCT04823052
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center & Children's Hospital, Chicago, Illinois, United States
A Study of OV101 in Individuals With Angelman Syndrome (AS)
- Conditions
- Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04106557
- Locations
- 🇳🇱
Ovid Therapeutics Investigative Site, Rotterdam, Netherlands
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT03882918
- Locations
- 🇮🇱
Ovid Therapeutics Investigative Site, Ramat Gan, Israel
Single Dose Pharmacokinetic (PK) Study
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03109756
- Locations
- 🇺🇸
Ovid Therapeutics Investigative Site, Nashville, Tennessee, United States
Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 490
- Registration Number
- NCT00807248
- Locations
- 🇷🇺
RU011, Yaroslavl, Russian Federation
🇷🇺RU014, Volgograd, Russian Federation
🇷🇺RU015, Moscow, Russian Federation
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
- Conditions
- Primary Insomnia
- First Posted Date
- 2005-12-16
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 520
- Registration Number
- NCT00266344
A Study of Gaboxadol in Primary Insomnia
- Conditions
- Primary Insomnia
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-03-30
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 505
- Registration Number
- NCT00209924
- Locations
- 🇸🇪
Non-US study, principal location:, Göteborg, Sweden
A Study of Gaboxadol in Primary Insomnia
- Conditions
- Primary Insomnia
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-03-30
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 600
- Registration Number
- NCT00209963
A Study of Gaboxadol in Primary Insomnia
- Conditions
- Primary Insomnia
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-03-30
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 320
- Registration Number
- NCT00209846
- Locations
- 🇸🇪
Non-US study, principal location:, Göteborg, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.